Abstract
It is essential to summarize independent prognostic factors of bilateral kidney cancer and to clarify how the second primary cancer develops under these prognostic factors. Patients first diagnosed with bilateral renal cancer between 1973 and 2015 were abstracted from the SEER database. The Kaplan-Meier survival curves were conducted to depict survival difference and the log-rank tests were used to determine statistical significance. Multivariate Cox proportion hazard regression analyses were established to evaluate statistical significance for survival probability of each substage. The data of the second primary cancer after bilateral renal cancer were collected by MP-SIR session. There were 847 cases of synchronous bilateral renal cancer and 1218 cases of metachronous bilateral renal cancer. The 5-year cancer-specific survival (CSS) rate of the synchronous bilateral renal cancer is 51.5% and it is 93.6% in the metachronous group. In the synchronous group, there exists a CSS difference among the age subgroups (p < 0.001), the behavior subgroups (p < 0.001), the tumor size subgroups (p = 0.044), and the stage subgroups (p < 0.001). And in the metachronous group, there was a statistical significance among the age subgroups (p < 0.001), the tumor size subgroups (p = 0.015), and the stage subgroups (p < 0.001). Only 5 cases were observed in the synchronous group as the second primary cancer, while 268 cases were discovered in the metachronous group. Compared with synchronous bilateral renal cancer, metachronous bilateral renal cancer had a better CSS. And the incidence of second primary cancer is higher in the metachronous group than in the synchronous group. Further studies should be conducted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdel-Rahman O. Risk of subsequent primary kidney cancer after another malignancy: a population-based study. Clin Genitourin Cancer. 2017;15(5):e747–54.
Joung JY, Kwon WA, Lim J, Oh CM, Jung KW, Kim SH, et al. Second primary cancer risk among kidney cancer patients in Korea: a population-based cohort study. Cancer Res Treat. 2018;50(1):293–301.
Wiklund F, Tretli S, Choueiri TK, Signoretti S, Fall K, Adami HO. Risk of bilateral renal cell cancer. J Clin Oncol. 2009;27(23):3737–41.
Berczi C, Thomas B, Bacso Z, Flasko T. Bilateral renal cancers: oncological and functional outcomes. Int Urol Nephrol. 2016;48(10):1617–22.
Singer EA, Vourganti S, Lin KY, Gupta GN, Pinto PA, Rastinehad AR, et al. Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of followup. J Urol. 2012;188(6):2084–8.
Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168(6):2395–400.
Parker WP, Cheville JC, Frank I, Zaid HB, Lohse CM, Boorjian SA, et al. Application of the stage, size, grade, and necrosis (SSIGN) score for clear cell renal cell carcinoma in contemporary patients. Eur Urol. 2017;71(4):665–73.
Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, et al. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol. 2014;32(5):431–7.
Chandrasekar T, Klaassen Z, Goldberg H, Kulkarni GS, Hamilton RJ, Fleshner NE. Metastatic renal cell carcinoma: Patterns and predictors of metastases-a contemporary population-based series. Urol Oncol. 2017;35(11):661 e667–14.
Chakraborty S, Tarantolo SR, Batra SK, Hauke RJ. Incidence and prognostic significance of second primary cancers in renal cell carcinoma. Am J Clin Oncol. 2013;36(2):132–42.
Rabbani F, Reuter VE, Katz J, Russo P. Second primary malignancies associated with renal cell carcinoma: influence of histologic type. Urology. 2000;56(3):399–403.
Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, et al. Second primary malignancies associated with renal cell carcinoma histological subtypes. J Urol. 2006;176(3):900–3 discussion 903-904.
Funding
This study was sponsored by the National Natural Science Foundation of China (Nos. 81472377, 81502192, 81672544).
Author information
Authors and Affiliations
Contributions
M Abudurexiti: project development, data collection, manuscript writing
J Wang and N Shao: data collection
W Zhu and F Wan: data analysis
B Dai: manuscript editing.
Y Zhu: project development
D Ye: supervision
Corresponding authors
Ethics declarations
Conflict of Interest
The authors declare that they have no conflicts of interest.
Ethical Approval
De-identification of SEER data was done before release and they do not contain any personally identification information. As the data are publicly available, no ethical approval is required.
Informed Consent
As the data are publicly available, no informed consent is required.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Medicine
Rights and permissions
About this article
Cite this article
Abudurexiti, M., Wang, J., Shao, N. et al. Prognosis of the Metachronous and Synchronous Bilateral Renal Cancer and Second Primary Cancer After the Bilateral Renal Cancer: a Population-Based Analysis. SN Compr. Clin. Med. 1, 900–904 (2019). https://doi.org/10.1007/s42399-019-00144-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s42399-019-00144-8